Mi Youn Seol and her colleagues have demonstrated that co-administration of PI3K isoform-selective inhibitors (p110α, p110β, p110γ, and p110δ) with radiation therapy can effectively decrease radioresistance and inhibit tumor growth in patients with non-small cell lung cancer (NSCLC). This evidence concerns the gene PIK3CD and neoplasm.